Terns Pharmaceuticals, Inc.
TERN
Rang in Aktien
#3584
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Aktienkurs
$52.95
Zuletzt synchronisiert: 2026-05-15
Marktkapitalisierung
$4.77B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
529.61%
Land
US
Handel Terns Pharmaceuticals, Inc. (TERN)
Kategorie
Healthcare
EPS für Terns Pharmaceuticals, Inc. (TERN)
EPS zum December 2025 TTM: $-1.03
Laut den aktuellen Finanzberichten und dem Aktienkurs von Terns Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-1.03. Am Ende des Jahres 2023 betrug das EPS $-1.27 ein Rückgang im Vergleich zu dem EPS von 2022, das $-1.67 betrug.
EPS-Verlauf von Terns Pharmaceuticals, Inc. von 2018 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-1.03 | -8.04% |
| 2024 | $-1.12 | -11.81% |
| 2023 | $-1.27 | -23.95% |
| 2022 | $-1.67 | -15.66% |
| 2021 | $-1.98 | 22.98% |
| 2020 | $-1.61 | -41.24% |
| 2019 | $-2.74 | 270.27% |
| 2018 | $-0.74 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -1,781.55% |
US
|
|
| $-7.98 | 674.76% |
US
|
|
| $-5.29 | 413.59% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,793.20% |
NL
|
